Patents Examined by Samantha L Shterengarts
-
Patent number: 12138254Abstract: The present invention relates to chronic nightly use of lasmiditan for the prevention of migraine, particularly therapy resistant migraine which is defined herein as migraine refractory to two or more prior monotherapy and/or dual therapy treatment or prevention regimens.Type: GrantFiled: September 3, 2019Date of Patent: November 12, 2024Assignee: Eli Lilly and CompanyInventors: Robert Russell Conley, Gudarz Davar, Kirk Willis Johnson
-
Patent number: 12139467Abstract: Disclosed are methods for synthesizing cannabielsoin (CBE) and or analogs thereof. In particular, the present disclosure provides methods for synthesizing CBE or analogs thereof comprising steps of providing a cannabinoid composition that comprises cannabidiol (CBD) or analogs thereof; combining the cannabinoid composition with an agent comprising a ketone functional group; and contacting the cannabinoid composition with an oxidizing agent or exposing the cannabinoid composition to electromagnetic radiation.Type: GrantFiled: July 26, 2021Date of Patent: November 12, 2024Assignee: Canopy Growth CorporationInventors: Mahmood Azizpour Fard, Ben Geiling, Mohammadmehdi Haghdoost Manjili
-
Patent number: 12134625Abstract: Pyrrolo[2,1-f][1,2,4]triazine compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of pyrrolo[2,1-f][1,2,4]triazine compounds or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, viral infections, and osteoarthritis).Type: GrantFiled: October 12, 2022Date of Patent: November 5, 2024Assignee: BioSplice Therapeutics, Inc.Inventors: Gopi Kumar Mittapalli, Sunil Kumar K C, Chi Ching Mak, Brian Joseph Hofilena, Lewis Daniel Turner, Brian Walter Eastman, Ramkrishna Reddy Vakiti, Joseph Timothy Marakovits
-
Patent number: 12134588Abstract: Described herein are epinephrine salts, specifically the epinephrine malonate salt; the epinephrine malonate salt in crystalline form; a pharmaceutical composition comprising epinephrine malonate; a sublingual or buccal pharmaceutical composition comprising epinephrine malonate in crystalline form; and a method for treating a patient comprising administering a pharmaceutical composition of epinephrine malonate in crystalline form.Type: GrantFiled: November 18, 2022Date of Patent: November 5, 2024Assignee: Biothea Pharma, Inc.Inventors: Jean-Pierre Sommadossi, Adel Moussa
-
Patent number: 12129250Abstract: The invention provides a novel class of therapeutic agents that are safe and effective TYK2 inhibitors and pharmaceutical compositions of these compounds and methods of preparation and use thereof against various TYK2-mediated diseases and disorders.Type: GrantFiled: September 25, 2023Date of Patent: October 29, 2024Assignee: LYNK PHARMACEUTICALS CO. LTD.Inventors: Zhaokui Wan, Michael Lawrence Vazquez, Gurmit Grewal, Xiaodong Li, Lin Su, Jingyu Wu
-
Patent number: 12128025Abstract: The invention described here provides ready-to-use (RTU) pharmaceutical compositions in single unit dose packaging, such compositions including ascorbic acid compound(s), such as sodium ascorbate, and one or more pharmaceutically acceptable excipients (e.g., a carrier and optionally other agents, such as a tonicity agent, a chelator, or both). The compositions provided by the invention are stable when stored at 20° C. to 25° C.±2° C. for at least about 3 months. Compositions provided by the invention comprise an osmolality of between about 270 mOsm/kg to about 340 mOsm/kg and do not require dilution or further manipulation prior to use. In certain aspects, the invention comprises methods of using such compositions in the treatment of diseases, conditions, or symptoms related to vitamin C deficiency, such as, in specific embodiments, scurvy.Type: GrantFiled: December 9, 2022Date of Patent: October 29, 2024Assignee: Somerset Therapeutics, LLCInventors: Prem Sagar Akasapu, Veerappan Subramanian, Ilango Subramanian
-
Patent number: 12122742Abstract: This patent document discloses novel compounds and methods of preventing or treating diseases or conditions related to Keap1-Nrf2 interaction activity by use of the novel compounds. As direct inhibitors of Keap1-Nrf2 interaction, the compounds disclosed herein are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential dmg candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, Parkinson's, and inflammatory bowel disease including ulcerative colitis.Type: GrantFiled: January 16, 2020Date of Patent: October 22, 2024Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Longqin Hu, Dhulfiqar A. Abed
-
Patent number: 12122788Abstract: The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.Type: GrantFiled: January 4, 2023Date of Patent: October 22, 2024Assignee: Vertex Pharmaceuticals IncorporatedInventors: Paul Angell, John E. Cochran, Benjamin J. Littler, David Siesel, Armando Urbina, Corey Don Anderson, Jeremy J. Clemens, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Peter Grootenhuis, Sara Sabina Hadida Ruah, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Jinglan Zhou
-
Patent number: 12115174Abstract: Disclosed are pharmaceutical compositions comprising a lyophilized compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, and methods of using the same for treating cancer.Type: GrantFiled: August 15, 2019Date of Patent: October 15, 2024Assignee: AstraZeneca ABInventors: Paul Gellert, Kathryn Hill, Richard Storey
-
Patent number: 12116343Abstract: The disclosure provides at least one entity chosen from compounds of Formula (I) pharmaceutically acceptable salts thereof, solvates of any of the foregoing, and deuterated derivatives of any of the foregoing, compositions comprising the same, and methods of using the same, including use in treating APOL1 mediated kidney disease.Type: GrantFiled: January 28, 2021Date of Patent: October 15, 2024Assignee: Vertex Pharmaceuticals IncorporatedInventors: Leslie A. Dakin, Timothy J. Senter, Jingrong Cao, Jon H. Come, Francois Denis, Warren A. Dorsch, Anne Fortier, Martine Hamel, Elaine B. Krueger, Brian Ledford, Francois Maltais, Suganthini S. Nanthakumar, Olivier Nicolas, Camil E. Sayegh, Tiansheng Wang, Stephane Dorich, Lee Fader, Claudio Sturino, Janek Szychowski
-
Patent number: 12110277Abstract: The present disclosures are directed to processes for synthesizing (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide (“nirogacestat”).Type: GrantFiled: September 1, 2022Date of Patent: October 8, 2024Assignee: SPRINGWORKS THERAPEUTICS, INC.Inventors: Kristin Patterson, Mark Hatcher
-
Patent number: 12109213Abstract: The invention provides fused heterocyclic organic compounds such as dihydropyrazolopyridotriazinones, compositions containing such compounds, medical kits, and methods for using such compounds and compositions for body contouring and/or reduction of fat in a subject.Type: GrantFiled: July 6, 2022Date of Patent: October 8, 2024Assignee: Alevere Medical CorporationInventor: Tim Kamerzell
-
Patent number: 12102682Abstract: Embodiments of the present disclosure provide an injectable photothermal hydrogel based on melanin and a preparation method and an application thereof. The injectable photothermal hydrogel is a hydroxypropyl chitosan/bis-amino polyethylene glycol modified melanin nanoparticles (HPCS/MP) hydrogel. The HPCS/MP hydrogel is prepared by mixing bis-amino polyethylene glycol modified melanin nanoparticles (MP) with hydroxypropyl chitosan (HPCS). The MP is synthesized by an amidation reaction of the melanin and the bis-amino PEG. A ratio of a volume of an MP solution to a volume of an HPCS solution in the HPCS/MP hydrogel is 4:6. A concentration of the MP solution is 20 wt %. A concentration of the HPCS solution is 4 wt %.Type: GrantFiled: March 1, 2024Date of Patent: October 1, 2024Assignee: OCEAN UNIVERSITY OF CHINAInventors: Jing Chang, Lili Guo, Lan Guo, Jishang Sun, Cuiyao Li, Baoqin Han
-
Patent number: 12098133Abstract: Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.Type: GrantFiled: December 5, 2022Date of Patent: September 24, 2024Assignee: CV6 Therapeutics (NI) LimitedInventors: Mark Spyvee, Pravin S. Shirude
-
Patent number: 12091502Abstract: A heterobifunctional monodispersed polyethylene glycol represented by the formula (1): wherein X1 and Y1 are each an atomic group containing a functional group capable of forming a covalent bond upon a reaction with a functional group present in a biofunctional molecule, the functional group contained in the atomic group X1 and the functional group contained in the atomic group Y1 are different from each other; R1 is a hydrocarbon group having from 1 to 7 carbon atoms or a hydrogen atom; n is an integer of 3 to 72; 1 is an integer of 2 to 72; and A1, B1 and C1 are as defined herein.Type: GrantFiled: March 11, 2019Date of Patent: September 17, 2024Assignee: NOF CORPORATIONInventors: Kohei Yoshimura, Takuma Tsubusaki, Mika Hamura, Yuki Matsuno
-
Patent number: 12091419Abstract: A method for preparing dihydroartemisinin bulk drug in single process comprises: S1. dissolving artemisinin in aprotic solvent; S2. adding phase transfer catalyst and reducing agent in sequence to cause a reduction reaction with artemisinin; S3. adjusting the pH of the reaction system obtained in step S2 to 5-7 with acid solution, adding water and stirring, separating the liquids, extracting the aqueous phase obtained by the separation with the same aprotic solvent as in step S1, combining the organic phase obtained by extraction and separation, washing with water, and drying, obtaining dried organic phase; S4. placing the dried organic phase obtained in step S3 in a crystallization device that has the functions of crystallization-press filtration-drying, and then the crystals are precipitated, concentrated, press-filtered, and dried to obtain the refined dihydroartemisinin.Type: GrantFiled: February 20, 2020Date of Patent: September 17, 2024Assignee: Vinsce Bio-pharm (Suzhou) Co., Ltd.Inventors: Xuedong Peng, Mei Zhang, Jinzhao Zhao, Yongyi Yan
-
Patent number: 12091388Abstract: The present disclosure relates to solid state forms of Reproxalap salts, processes for the preparation thereof, pharmaceutical formulations/compositions thereof, and methods of use thereof.Type: GrantFiled: December 12, 2019Date of Patent: September 17, 2024Assignee: TEVA PHARMACEUTICALS INTERNATIONAL GMBHInventors: Anantha Rajmohan Muthusamy, Sundara Lakshmi Kanniah, Rahul Kumar Reddy Putikum, Sudhanshu Saxena, Amol Bandal
-
Patent number: 12084424Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.Type: GrantFiled: May 18, 2023Date of Patent: September 10, 2024Assignee: Novartis AGInventors: Luigi Franchi, Shomir Ghosh, Gary Glick, Jason Katz, Anthony William Opipari, Jr., William Roush, Hans Martin Seidel, Dong-Ming Shen, Shankar Venkatraman, David Guenther Winkler
-
Patent number: 12084448Abstract: A process is provided, comprising reacting a (hetero)aryl 1,3-dipole compound with a (hetero)cycloalkyne, wherein the (hetero)aryl 1,3-dipole compound comprises a 1,3-dipole functional group bonded to a (hetero)aryl group, and wherein the (hetero)aryl 1,3-dipole compound is a (hetero)aryl azide or a (hetero)aryl diazo compound; wherein: (i) the (hetero)aryl group of the (hetero)aryl 1,3-dipole compound comprises a substituent (ii) the (hetero)aryl group of the (hetero)aryl 1,3-dipole compound is an electron-poor (hetero)aryl group and wherein the (hetero)cycloalkyne is a (hetero)cyclooctyne or a (hetero)cyclononyne according to Formula (1). The invention also relates to the products obtainable by the process according to the invention.Type: GrantFiled: October 15, 2021Date of Patent: September 10, 2024Assignee: Synaffix B.V.Inventors: Floris Louis Van Delft, Frederik Jan Dommerholt
-
Patent number: 12083124Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.Type: GrantFiled: January 26, 2023Date of Patent: September 10, 2024Assignee: Incyte CorporationInventors: Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Michael Witten, Yao Xu, Hai Fen Ye, Ke Zhang, Peng Zhao, Wenqing Yao